Rifaximin for the treatment of active pouchitis: A randomized, double-blind, placebo-controlled pilot study

Kim L. Isaacs, Robert S. Sandler, Maria T Abreu, Michael F. Picco, Stephen B. Hanauer, Stephen J. Bickston, Daniel Present, Francis A. Farraye, Douglas Wolf, William J. Sandborn

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Background: The efficacy of the nonabsorbable antibiotic rifaximin in patients with active acute or chronic pouchitis is unknown. Methods: We performed a placebo-controlled pilot trial to evaluate the efficacy and safety of rifaximin in patients with active pouchitis. Eighteen patients with active pouchitis were randomized to receive oral rifaximin 400 mg or placebo 3 times daily for 4 weeks. Active pouchitis was defined as a total Pouchitis Disease Activity Index (PDAI) score = 7 points. Clinical remission was defined as a PDAI score <7 points and a decrease in the baseline PDAI score = 3 points. The primary analysis was clinical remission at week 4. Results: Eight patients were randomized to rifaximin and 10 patients were randomized to placebo. One patient in the placebo group did not have a post-baseline efficacy evaluation and was excluded from the efficacy analysis. Two of 8 patients (25%) treated with rifaximin were in clinical remission at week 4 compared to 0 of 9 patients (0%) treated with placebo (P = 0.2059). None of 8 patients in the rifaximin group withdrew from the trial prior to week 4. Two of 9 patients in the placebo group withdrew prior to week 4 due to lack of efficacy and were categorized as treatment failures. Conclusions: Clinical remission occurred more frequently in patients treated with rifaximin 400 mg 3 times daily but the difference was not significant in this pilot study. A larger trial would be required to determine if rifaximin is effective for the treatment of active pouchitis. Rifaximin was well tolerated.

Original languageEnglish
Pages (from-to)1250-1255
Number of pages6
JournalInflammatory Bowel Diseases
Volume13
Issue number10
DOIs
StatePublished - Oct 1 2007
Externally publishedYes

Fingerprint

rifaximin
Pouchitis
Placebos
Therapeutics
Treatment Failure

Keywords

  • Antibiotics
  • Inflammatory bowel disease
  • Pouchitis
  • Ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Isaacs, K. L., Sandler, R. S., Abreu, M. T., Picco, M. F., Hanauer, S. B., Bickston, S. J., ... Sandborn, W. J. (2007). Rifaximin for the treatment of active pouchitis: A randomized, double-blind, placebo-controlled pilot study. Inflammatory Bowel Diseases, 13(10), 1250-1255. https://doi.org/10.1002/ibd.20187

Rifaximin for the treatment of active pouchitis : A randomized, double-blind, placebo-controlled pilot study. / Isaacs, Kim L.; Sandler, Robert S.; Abreu, Maria T; Picco, Michael F.; Hanauer, Stephen B.; Bickston, Stephen J.; Present, Daniel; Farraye, Francis A.; Wolf, Douglas; Sandborn, William J.

In: Inflammatory Bowel Diseases, Vol. 13, No. 10, 01.10.2007, p. 1250-1255.

Research output: Contribution to journalArticle

Isaacs, KL, Sandler, RS, Abreu, MT, Picco, MF, Hanauer, SB, Bickston, SJ, Present, D, Farraye, FA, Wolf, D & Sandborn, WJ 2007, 'Rifaximin for the treatment of active pouchitis: A randomized, double-blind, placebo-controlled pilot study', Inflammatory Bowel Diseases, vol. 13, no. 10, pp. 1250-1255. https://doi.org/10.1002/ibd.20187
Isaacs, Kim L. ; Sandler, Robert S. ; Abreu, Maria T ; Picco, Michael F. ; Hanauer, Stephen B. ; Bickston, Stephen J. ; Present, Daniel ; Farraye, Francis A. ; Wolf, Douglas ; Sandborn, William J. / Rifaximin for the treatment of active pouchitis : A randomized, double-blind, placebo-controlled pilot study. In: Inflammatory Bowel Diseases. 2007 ; Vol. 13, No. 10. pp. 1250-1255.
@article{c1bc534de047439f87802f5e0a51dca1,
title = "Rifaximin for the treatment of active pouchitis: A randomized, double-blind, placebo-controlled pilot study",
abstract = "Background: The efficacy of the nonabsorbable antibiotic rifaximin in patients with active acute or chronic pouchitis is unknown. Methods: We performed a placebo-controlled pilot trial to evaluate the efficacy and safety of rifaximin in patients with active pouchitis. Eighteen patients with active pouchitis were randomized to receive oral rifaximin 400 mg or placebo 3 times daily for 4 weeks. Active pouchitis was defined as a total Pouchitis Disease Activity Index (PDAI) score = 7 points. Clinical remission was defined as a PDAI score <7 points and a decrease in the baseline PDAI score = 3 points. The primary analysis was clinical remission at week 4. Results: Eight patients were randomized to rifaximin and 10 patients were randomized to placebo. One patient in the placebo group did not have a post-baseline efficacy evaluation and was excluded from the efficacy analysis. Two of 8 patients (25{\%}) treated with rifaximin were in clinical remission at week 4 compared to 0 of 9 patients (0{\%}) treated with placebo (P = 0.2059). None of 8 patients in the rifaximin group withdrew from the trial prior to week 4. Two of 9 patients in the placebo group withdrew prior to week 4 due to lack of efficacy and were categorized as treatment failures. Conclusions: Clinical remission occurred more frequently in patients treated with rifaximin 400 mg 3 times daily but the difference was not significant in this pilot study. A larger trial would be required to determine if rifaximin is effective for the treatment of active pouchitis. Rifaximin was well tolerated.",
keywords = "Antibiotics, Inflammatory bowel disease, Pouchitis, Ulcerative colitis",
author = "Isaacs, {Kim L.} and Sandler, {Robert S.} and Abreu, {Maria T} and Picco, {Michael F.} and Hanauer, {Stephen B.} and Bickston, {Stephen J.} and Daniel Present and Farraye, {Francis A.} and Douglas Wolf and Sandborn, {William J.}",
year = "2007",
month = "10",
day = "1",
doi = "10.1002/ibd.20187",
language = "English",
volume = "13",
pages = "1250--1255",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Rifaximin for the treatment of active pouchitis

T2 - A randomized, double-blind, placebo-controlled pilot study

AU - Isaacs, Kim L.

AU - Sandler, Robert S.

AU - Abreu, Maria T

AU - Picco, Michael F.

AU - Hanauer, Stephen B.

AU - Bickston, Stephen J.

AU - Present, Daniel

AU - Farraye, Francis A.

AU - Wolf, Douglas

AU - Sandborn, William J.

PY - 2007/10/1

Y1 - 2007/10/1

N2 - Background: The efficacy of the nonabsorbable antibiotic rifaximin in patients with active acute or chronic pouchitis is unknown. Methods: We performed a placebo-controlled pilot trial to evaluate the efficacy and safety of rifaximin in patients with active pouchitis. Eighteen patients with active pouchitis were randomized to receive oral rifaximin 400 mg or placebo 3 times daily for 4 weeks. Active pouchitis was defined as a total Pouchitis Disease Activity Index (PDAI) score = 7 points. Clinical remission was defined as a PDAI score <7 points and a decrease in the baseline PDAI score = 3 points. The primary analysis was clinical remission at week 4. Results: Eight patients were randomized to rifaximin and 10 patients were randomized to placebo. One patient in the placebo group did not have a post-baseline efficacy evaluation and was excluded from the efficacy analysis. Two of 8 patients (25%) treated with rifaximin were in clinical remission at week 4 compared to 0 of 9 patients (0%) treated with placebo (P = 0.2059). None of 8 patients in the rifaximin group withdrew from the trial prior to week 4. Two of 9 patients in the placebo group withdrew prior to week 4 due to lack of efficacy and were categorized as treatment failures. Conclusions: Clinical remission occurred more frequently in patients treated with rifaximin 400 mg 3 times daily but the difference was not significant in this pilot study. A larger trial would be required to determine if rifaximin is effective for the treatment of active pouchitis. Rifaximin was well tolerated.

AB - Background: The efficacy of the nonabsorbable antibiotic rifaximin in patients with active acute or chronic pouchitis is unknown. Methods: We performed a placebo-controlled pilot trial to evaluate the efficacy and safety of rifaximin in patients with active pouchitis. Eighteen patients with active pouchitis were randomized to receive oral rifaximin 400 mg or placebo 3 times daily for 4 weeks. Active pouchitis was defined as a total Pouchitis Disease Activity Index (PDAI) score = 7 points. Clinical remission was defined as a PDAI score <7 points and a decrease in the baseline PDAI score = 3 points. The primary analysis was clinical remission at week 4. Results: Eight patients were randomized to rifaximin and 10 patients were randomized to placebo. One patient in the placebo group did not have a post-baseline efficacy evaluation and was excluded from the efficacy analysis. Two of 8 patients (25%) treated with rifaximin were in clinical remission at week 4 compared to 0 of 9 patients (0%) treated with placebo (P = 0.2059). None of 8 patients in the rifaximin group withdrew from the trial prior to week 4. Two of 9 patients in the placebo group withdrew prior to week 4 due to lack of efficacy and were categorized as treatment failures. Conclusions: Clinical remission occurred more frequently in patients treated with rifaximin 400 mg 3 times daily but the difference was not significant in this pilot study. A larger trial would be required to determine if rifaximin is effective for the treatment of active pouchitis. Rifaximin was well tolerated.

KW - Antibiotics

KW - Inflammatory bowel disease

KW - Pouchitis

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=35348991729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348991729&partnerID=8YFLogxK

U2 - 10.1002/ibd.20187

DO - 10.1002/ibd.20187

M3 - Article

C2 - 17567869

AN - SCOPUS:35348991729

VL - 13

SP - 1250

EP - 1255

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 10

ER -